Aytu BioPharma, Inc.
AYTU · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $66 | $65 | $107 | $97 |
| % Growth | 1.8% | -39.3% | 11.1% | – |
| Cost of Goods Sold | $21 | $16 | $41 | $46 |
| Gross Profit | $46 | $49 | $67 | $50 |
| % Margin | 69% | 75.3% | 62% | 52% |
| R&D Expenses | $1 | $3 | $4 | $13 |
| G&A Expenses | $17 | $20 | $29 | $31 |
| SG&A Expenses | $38 | $42 | $70 | $70 |
| Sales & Mktg Exp. | $21 | $22 | $41 | $39 |
| Other Operating Expenses | $14 | $6 | $10 | $78 |
| Operating Expenses | $54 | $51 | $84 | $160 |
| Operating Income | -$8 | -$2 | -$17 | -$110 |
| % Margin | -11.8% | -2.4% | -15.9% | -113.7% |
| Other Income/Exp. Net | -$6 | -$9 | $0 | $1 |
| Pre-Tax Income | -$14 | -$10 | -$17 | -$109 |
| Tax Expense | $0 | $2 | $0 | -$0 |
| Net Income | -$14 | -$16 | -$17 | -$109 |
| % Margin | -20.4% | -24.3% | -15.9% | -112.5% |
| EPS | -2.16 | -2.86 | -5.11 | -74.01 |
| % Growth | 24.5% | 44% | 93.1% | – |
| EPS Diluted | -2.16 | -2.86 | -5.11 | -74.01 |
| Weighted Avg Shares Out | 6 | 6 | 3 | 1 |
| Weighted Avg Shares Out Dil | 6 | 6 | 3 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4 | $5 | $5 | $147 |
| Depreciation & Amortization | $5 | $7 | $9 | $10 |
| EBITDA | -$5 | $1 | -$3 | -$28 |
| % Margin | -7% | 2.2% | -3% | -28.9% |